*Corresponding author, MediCom Worldwide, Inc, 101 Washington Street, Morrisville, PA 19067,
e-mail: gtombler@medicaled.com
Activity Release Date: November 15, 2012
Period of Validity: November 15, 2013
Program Overview
This activity presents highlights from a satellite symposium held in conjunction with the European School of Haematology (ESH)–International Chronic Myeloid Leukemia Foundation (iCMLf) 14th International Conference on Chronic Myeloid Leukemia: Biology and Therapy, held September 20–23, 2012, in Baltimore. Using clinical evidence as a guide, three world-renowned experts discuss overcoming barriers to improved chronic myeloid leukemia (CML) patient outcomes using a case-based format. Topics included addressing controversial issues regarding how to best assess response to tyrosine kinase inhibitor therapy, and how monitoring should be conducted. Strategies for overcoming imatinib (Gleevec) resistance and preventing it are currently available, including the recently approved tyrosine kinase inhibitor bosutinib (Bosulif) and omacetaxine (Synribo), which has a mechanism of action different from tyrosine kinase inhibitors, but additional options are still needed. Included in the discussions is the investigational third-generation tyrosine kinase inhibitor ponatinib. New next-generation tyrosine kinase inhibitors and alternative therapies, once made available, will open new questions regarding optimal selection and sequencing. Finally, the question of how a functional cure may be defined and whether tyrosine kinase inhibitor therapy can be discontinued has become an area of significant clinical interest.
Target Audience
This activity is designed for physicians, physician assistants, nurses, nurse practitioners, and other health-care professionals who have an interest in enhancing their knowledge and understanding of the management of CML.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recall evidence-based approaches for treatment response monitoring, assessing adherence, and tailoring of therapy based on responses
- Relate causes of primary and secondary resistance, appropriate testing and monitoring, as well as strategies for overcoming resistance
- Convey clinical findings relating to efficacy and safety, as well as trial limitations for agents undergoing investigation for overcoming tyrosine kinase inhibitor refractory disease
- Recognize how a cure for CML might be defined and whether discontinuation of treatment is currently an appropriate option for CML patients
Activity Instructions
This activity is eligible for credit through November 15, 2013. After this date, this activity will expire and no further credit will be awarded.
Expected time to complete this activity as designed: 60 minutes
The content of this supplement, Highlights of an ESH–iCMLf Satellite Symposium – Monitoring, Treatment Resistance, and Treatment Failure in Chronic Myeloid Leukemia: Breaking Barriers to Improved Outcomes and Looking Forward to a Cure, is a component of an online CME activity and CNE activity.
CE Accreditation
CME Credit
Accreditation Statement: The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit: The Medical College of Wisconsin designates this enduring material a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nursing Credit
Accreditation Statement: MediCom Worldwide, Inc, 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 12-330-295
Disclaimer
This material has been prepared based on a review of multiple sources of information, but it is not exhaustive of the subject matter. Participants are advised to critically appraise the information presented and encouraged to consult the above-mentioned resources as well as available literature on any product or device mentioned in this program.
Disclosure of Unlabeled Uses
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physicians’ Desk Reference.
Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and California State Board of Registered Nursing, MediCom Worldwide, Inc, requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Faculty Disclosures
Consistent with the current Accreditation Council for Continuing Medical Education policy, the CME Provider must be able to show that everyone who is in a position to control the content of an individual educational activity has disclosed all relevant financial relationships.
The CME Provider has a mechanism in place to identify and resolve any conflicts of interest discovered in the disclosure process. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant:
Jorge Cortes, MD, has received consultant fees as well as grant support related to research activities from ARIAD Pharmaceuticals, Inc; Bristol-Myers Squibb; ChemGenex Pharmaceuticals Ltd; Novartis AG; and Pfizer, Inc.
John Goldman, DM, FRCP, FRCPath, FMedSci, has received honoraria related to speakers’ bureau activities from Amgen, Inc; ARIAD Pharmaceuticals, Inc; Bristol-Myers Squibb; and Novartis AG.
Timothy Hughes, MD, MBBS, has received honoraria related to formal advisory activities and speakers’ bureau activities from ARIAD Pharmaceuticals, Inc; Bristol-Myers Squibb; and Novartis AG.
Planning Committee Disclosures
The individuals listed below from the Medical College of Wisconsin reported the following for this activity: Linda D. Caples, MBA, has no relevant financial relationships.
The individuals listed below from MediCom Worldwide, Inc, reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Eugene R. Tombler, PhD, Medical Director, have no relevant financial relationships. Gail V. Flores, PhD, and Marie Sabo Recine, MS, medical writers, have no relevant financial relationships.
This activity is sponsored by Medical College of Wisconsin and MediCom Worldwide, Inc.
This activity was supported by an unrestricted educational grant from ARIAD Pharmaceuticals, Inc.
